Source: Virtual Congress 2020 – Asthma pharmacology: clinical trials and mechanistic insights
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Quinta (Toulouse, France), F. Montastruc (Toulouse, France), V. Rousseau (Toulouse, France), A. Sommet (Toulouse, France), A. Touafchia (Toulouse, France), M. Galinier (Toulouse, France), L. Guilleminault (Toulouse, France). Late Breaking Abstract - Cardiovascular adverse events of drugs targeting IL-5 in severe asthma: a pharmacovigilance study. 3692

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - International, prospective real-world study of mepolizumab in patients with severe asthma at one year: REALITI-A Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Late Breaking Abstract - Cardiovascular risk and COPD in a population-based study Source: Virtual Congress 2021 – Asthma burden and management I Year: 2021 Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events: A population-based study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Monitoring asthma in children: treatment-related issues Source: International Congress 2014 – Monitoring asthma in children: results of the ERS Task Force Year: 2014 Late Breaking Abstract - Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Late Breaking Abstract - A key endpoint in viral challenge models of asthma exacerbations Source: International Congress 2019 – Airway physiology Year: 2019 Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) Source: Eur Respir J 2007; 30: Suppl. 51, 125s Year: 2007 Adverse events and cardiovasular effects of vilanterol in paediatric asthma: a systematic review Source: International Congress 2019 – Severe acute asthma and troublesome wheezing Year: 2019 Late Breaking Abstract - Early response to benralizumab in Canadians with severe eosinophilic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract - Reimbursement for asthma care is a universal barrier to achieving asthma symptom control: the SABINA III study Source: Virtual Congress 2020 – Personalised treatment of obstructive diseases Year: 2020 Late Breaking Abstract - Silent exacerbations: underreporting of COPD exacerbations in Poland Source: Virtual Congress 2020 – COPD and the impact of comorbidities Year: 2020 Metrics of salbutamol use as predictors of future adverse outcomes in asthma Source: Annual Congress 2013 –Quality of diagnosis and assessment in primary care Year: 2013 Late Breaking Abstract - Pharmacological and clinical management of severe asthma in 9 countries: An international survey of clinicians. Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 Late Breaking Abstract - Gender and asthma: Gender-dependent effects of obesity on allergic pulmonary inflammation Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Late Breaking Abstract - Defining a severe asthma super-responder: findings from a Delphi process Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 Late Breaking Abstract - Shared genetic origins of obesity and poor ICS response in children with asthma Source: Virtual Congress 2021 – Lung disease burden and management Year: 2021 Late Breaking Abstract - Long-term safety & durability of mepolizumab in life-threatening/seriously debilitating severe eosinophilic asthma (SEA): COSMEX Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Late Breaking Abstract - Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017 Late Breaking Abstract - Characterizing responders to benralizumab for severe asthma: pooled analysis of the SIROCCO and CALIMA studies Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017 Late Breaking Abstract - Exacerbation of asthma in childhood: seasonal pattern and risk factors. Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities Year: 2017